Zaynich (cefepime/zidebactam) access guide: novel AMR antibiotic for resistant cUTI

On May 29, 2026, the FDA approved Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible microorganisms. Zaynich is the first approved drug to use a β-lactam enhancer mechanism — pairing a fourth-generation cephalosporin with zidebactam, a first-in-class molecule that reinforces antibiotic activity against resistant Gram-negative pathogens.

This access guide is for infectious disease pharmacists, antimicrobial stewardship teams, hospital pharmacy committees, and payer medical directors who need to understand Zaynich's mechanism, clinical evidence, formulary positioning, stewardship considerations, and payer implications.

What Zaynich is and how it works

Zaynich is a combination of cefepime, an established fourth-generation cephalosporin, and zidebactam, a novel β-lactamase inhibitor and β-lactam enhancer developed by Wockhardt. It represents a new class of antibiotic mechanism.

Key parameters:

Zaynich's mechanism has two components:

• Cefepime binds to penicillin-binding proteins (PBPs) and disrupts bacterial cell-wall synthesis, the standard cephalosporin action.
• Zidebactam reinforces this activity through two mechanisms: it acts as a β-lactamase inhibitor that protects cefepime from degradation by certain resistance enzymes, and it independently binds to PBP2 to directly kill Gram-negative bacteria — a "β-lactam enhancer" effect that restores and amplifies cefepime's activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) organisms.

This dual mechanism allows Zaynich to overcome all clinically important resistance mechanisms in Gram-negative pathogens including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter baumannii, and Klebsiella pneumoniae — including carbapenem-resistant strains.

The AMR context: why this approval matters

More than 2.8 million antimicrobial-resistant infections occur each year in the United States, resulting in more than 35,000 deaths, according to the CDC. Gram-negative resistance is among the most urgent threats:

• Carbapenem-resistant Enterobacterales (CRE) are classified by the CDC as an urgent antimicrobial resistance threat
• Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales are increasingly common in both community and hospital settings
• MDR Pseudomonas aeruginosa and Acinetobacter baumannii pose significant treatment challenges in ICUs
• Complicated urinary tract infections are among the most common hospital-acquired infections and are increasingly caused by resistant organisms

The antibiotic pipeline has been thin for decades. Zaynich is one of the few new antibiotics targeting MDR and XDR Gram-negative infections to reach the US market, and it is the first novel chemical entity (NCE) from an Indian pharmaceutical company to receive FDA approval — a milestone for Wockhardt, which invested 25 years of research in antibiotic discovery.

ENHANCE-1: the pivotal phase 3 trial

The FDA approval was supported by the ENHANCE-1 trial, a phase 3 randomized, double-blind, multicenter study comparing Zaynich with meropenem in hospitalized adults with cUTI or acute pyelonephritis.

Key findings:

• Trial size: 530 patients enrolled across 64 sites in the US, Europe, Latin America, China, and India
• Primary endpoint met: Zaynich achieved a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem. The treatment difference was 20.6% (95% CI 12.3–29.5), demonstrating superiority to meropenem.
• Clinical cure rate: In broader analyses, Zaynich demonstrated a 96.8% clinical cure rate across Phase III studies for cUTI, significantly outperforming meropenem.
• Safety: Zaynich was generally well tolerated in the trial, with an adverse event profile consistent with the cephalosporin class.
• Spectrum: The trial demonstrated efficacy against a range of Gram-negative pathogens, including MDR organisms.
• Compassionate use data: Under compassionate use and Expanded Access IND programs, Zaynich has been used in 85 cases of XDR Gram-negative infections across India, the US, Malaysia, and France. In 30 critically ill patients with life-threatening drug-resistant infections, Zaynich achieved a 100% clinical cure rate. Notable cases include successful treatment of XDR Pseudomonas infections in immunocompromised cancer patients at US academic medical centers.

The prescribing information includes a warning about serious neurologic adverse reactions in geriatric patients with renal insufficiency given unadjusted doses of cefepime — consistent with the known cefepime safety profile and existing label warnings for cefepime-containing products.

Wockhardt has stated that future studies are planned to expand Zaynich's indications to include bloodstream infections, pneumonia, and hospital-acquired infections, which would significantly broaden its clinical utility.

Access implications for payers and health systems

Formulary positioning

Zaynich will likely be positioned as a reserve antibiotic for MDR Gram-negative infections, similar to other recently approved agents like meropenem-vaborbactam (Vabomere), imipenem-relebactam (Recarbrio), and cefiderocol (Fetroja). Its initial indication is limited to cUTI/pyelonephritis, but its spectrum of activity against XDR pathogens gives it potential utility beyond that indication once broader data are available.

Expected formulary considerations:

• Prior authorization requiring documented resistance to first-line agents or culture confirmation of MDR/XDR Gram-negative pathogen
• Infectious disease consultation requirements, consistent with IV antibiotic stewardship protocols at many health systems
• Restricted indication: Formulary use initially limited to cUTI/pyelonephritis per FDA-approved indication
• Reserve antibiotic classification: Stewardship programs should classify Zaynich as a "last-resort" agent for documented resistant infections, similar to carbapenem-sparing strategies

Payer and benefit design

As an IV antibiotic administered in hospital settings, Zaynich will be adjudicated under the medical benefit:

• Medical benefit management rather than pharmacy benefit — hospital formulary committees and P&T committees will be the primary gatekeepers
• Buy-and-bill economics may apply for outpatient infusion centers administering Zaynich
• J-code assignment: Zaynich will need a permanent HCPCS J-code for outpatient billing. Until a permanent code is assigned, interim billing codes (like J3490 or J8999 for unclassified drugs) may be used, creating claim-denial risk for hospital outpatient departments
• Diagnosis coding: Payers will look for specific ICD-10 codes confirming cUTI/pyelonephritis and, potentially, documented resistance

Site-of-care considerations

Zaynich's 8-hour dosing interval (every 8 hours) means:

• Inpatient administration is the primary setting for the approved indication
• Outpatient parenteral antibiotic therapy (OPAT) programs may use Zaynich for step-down from acute care, but the TID dosing complicates home infusion logistics
• Hospital discharge planning teams will need to coordinate medical benefit authorization for continued outpatient therapy

Comparison with other MDR Gram-negative antibiotics

Zaynich differentiates by not containing a carbapenem, making it a carbapenem-sparing option — an important stewardship consideration given the emphasis on preserving carbapenem effectiveness.

Pricing outlook

Wockhardt has not disclosed US pricing for Zaynich. IV specialty antibiotics for MDR infections in the US typically range from $1,500 to $5,000 per day of therapy, depending on the agent and duration.

Pricing factors:

• The QIDP designation provides 5 additional years of marketing exclusivity but does not constrain pricing
• Wockhardt is targeting a $7 billion market opportunity for the antibiotic globally
• Payers will evaluate Zaynich against the total cost of MDR infection treatment, including extended hospital stays ($2,000–$4,000/day), alternative IV antibiotics, and infection-control costs
• Health systems with antimicrobial stewardship programs may find Zaynich cost-effective for documented MDR infections if it shortens therapy duration or avoids carbapenem use

Global regulatory status

• United States: FDA approved May 29, 2026
• India: Approved by the Drugs Controller General of India (DCGI) on May 27, 2026, for cUTI including pyelonephritis with or without concurrent Gram-negative bacteremia — a broader indication than the US approval, which does not include bacteremia
• European Union: Marketing Authorization Application (MAA) submitted to the European Medicines Agency; under review
• Future indications: Wockhardt has stated plans to expand indications to bloodstream infections, pneumonia, and hospital-acquired infections

What to watch

• Wockhardt US launch execution: Distribution network, pricing announcement, and patient support programs
• J-code assignment: When CMS assigns a permanent HCPCS J-code for outpatient billing — interim codes create claim-denial risk
• Hospital P&T committee reviews: How health systems incorporate Zaynich into antibiograms and stewardship protocols
• Expanded indications: Phase 3 trials for bloodstream infections, pneumonia, and HABP/VABP would significantly broaden formulary utility
• Payer stewardship criteria: Whether PBMs and health plans develop specific PA criteria for Zaynich versus existing MDR Gram-negative agents
• Real-world resistance data: Post-marketing surveillance of resistance patterns will inform Zaynich's long-term stewardship positioning
• European approval: EMA decision will determine whether Zaynich gains global market access
• India launch: Wockhardt has indicated a mid-2026 India launch — price and access in India may differ substantially from US pricing

Sources

• FDA. "Novel Drug Approvals for 2026." Updated June 1, 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
• Wockhardt. "Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam)." Press release, June 1, 2026. https://www.prnewswire.com/news-releases/wockhardt-receives-us-fda-approval-for-zaynich-cefepime-and-zidebactam-a-novel-intravenous-antibiotic-for-the-treatment-of-adult-patients-with-complicated-urinary-tract-infection-including-pyelonephritis-302786691.html
• FDA. Zaynich Prescribing Information. Revised May 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220787Orig1s000lbl.pdf
• American Pharmaceutical Review. "Wockhardt Wins FDA Approval for Novel cUTI Antibiotic ZAYNICH." June 2026. https://www.americanpharmaceuticalreview.com/1315-News/625905-Wockhardt-Wins-FDA-Approval-for-Novel-cUTI-Antibiotic-ZAYNICH
• CDC. "Antibiotic Resistance Threats in the United States, 2019." U.S. Department of Health and Human Services. https://www.cdc.gov/drugresistance/biggest-threats.html
• CDC. "About Antimicrobial Resistance." Updated January 31, 2025. https://www.cdc.gov/antimicrobial-resistance/about/index.html
• Marantidis J, Sussman RD. "Unmet Needs in Complicated Urinary Tract Infections." Infection and Drug Resistance, 16:1391–1405, 2023. https://www.dovepress.com/unmet-needs-in-complicated-urinary-tract-infections-challenges-recomme-peer-reviewed-fulltext-article-IDR